Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)

American Journal of Kidney Diseases

Volumn 54, Issue 1, 2009, Pages 59-69

  Pfeffer, Marc A ^a   Burdmann, Emmanuel A ^a   Chen, Chao Yin ^a   Cooper, Mark E ^a   de Zeeuw, Dick ^a   Eckardt, Kai Uwe ^a   Ivanovich, Peter ^a   Kewalramani, Reshma ^a   Levey, Andrew S ^a   Lewis, Eldrin F ^a   McGill, Janet ^a   McMurray, John J V ^a   Parfrey, Patrick ^a   Parving, Hans Henrik ^a   Remuzzi, Giuseppe ^a   Singh, Ajay K ^a   Solomon, Scott D ^a   Toto, Robert ^a   Uno, Hajime ^a  

^a NONE

Author keywords

anemia; chronic kidney disease; diabetes; Erythropoiesis stimulating agents

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANTIANEMIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ORAL ANTIDIABETIC AGENT; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; RISK; STROKE;

AGED; ANEMIA; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; ERYTHROPOIETIN; FEMALE; GLOMERULAR FILTRATION RATE; HEMATINICS; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROTEINURIA; RISK FACTORS; TREATMENT OUTCOME;

EID: 67449158735     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.04.008     Document Type: Article

References (35)

1. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
2. Booth G.L., Kapral M.K., Fung K., and Tu J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study. Lancet 368 (2006) 29-36
3. Stengel B., Billon S., Van Dijk P.C., et al. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 18 (2003) 1824-1833
4. Foley R.N., and Collins A.J. End-stage renal disease in the United States: An update from the United States Renal Data System. J Am Soc Nephrol 18 (2007) 2644-2648
5. Turnbull F., Neal B., Algert C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 165 (2005) 1410-1419
6. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
7. Gaede P., Lund-Andersen H., Parving H.H., and Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
8. Locatelli F., Pisoni R.L., Combe C., et al. Anemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19 (2004) 121-132
9. Foley R.N., Parfrey P.S., Harnett J.D., et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 41 (2003) 520 author reply, 521
10. Keane W.F., Brenner B.M., de Zeeuw D., et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 63 (2003) 1499-1507
11. Pfeffer M.A., Solomon S.D., Singh A.K., Ivanovich P., and McMurray J.J. Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med 6 suppl 3 (2005) S35-S41
12. Mix T.C., Brenner R.M., Cooper M.E., et al. Rationale-Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149 (2005) 408-413
13. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
14. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
15. Strippoli G.F., Tognoni G., Navaneethan S.D., Nicolucci A., and Craig J.C. Haemoglobin targets: We were wrong, time to move on. Lancet 369 (2007) 346-350
16. Pfeffer M.A. An ongoing study of anemia correction in chronic kidney disease [letter]. N Engl J Med 356 (2007) 959-961
17. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
18. Fox C.S., Coady S., Sorlie P.D., et al. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study. Circulation 115 (2007) 1544-1550
19. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
20. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
21. Weiner D.E., Tighiouart H., Vlagopoulos P.T., et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16 (2005) 1803-1810
22. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007) 2109-2122
23. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: Are we being misled?. Ann Intern Med 125 (1996) 605-613
24. Pfeffer M.A. Critical missing data in erythropoiesis-stimulating agents in CKD: First beat placebo. Am J Kidney Dis 51 (2008) 366-369
25. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 (1989) 992-1000
26. Ma J.Z., Ebben J., Xia H., and Collins A.J. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10 (1999) 610-619
27. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
28. Besarab A., Goodkin D.A., and Nissenson A.R. The normal hematocrit study-Follow-up. N Engl J Med 358 (2008) 433-434
29. Revicki D.A., Brown R.E., Feeny D.H., et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (1995) 548-554
30. Ritz E., Laville M., Bilous R.W., et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 49 (2007) 194-207
31. Phrommintikul A., Haas S.J., Elsik M., and Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369 (2007) 381-388
32. Levin A. Understanding recent haemoglobin trials in CKD: Methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 22 (2007) 309-312
33. Locatelli F., Nissenson A.R., Barrett B.J., et al. Clinical practice guidelines for anemia in chronic kidney disease: Problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 74 (2008) 1237-1240
34. FDA black box warning for Aranesp. http://www.fda.gov/cder/foi/label/2008/103951s5195PI.pdf. Accessed May 15, 2009
35. Gandhi G.Y., Murad M.H., Fujiyoshi A., et al. Patient-important outcomes in registered diabetes trials. JAMA 299 (2008) 2543-2549